EMA backs Wegovy tablets: Oral semaglutide nears EU approval
The EMA has recommended approval of Wegovy tablets (oral semaglutide) for weight management - a first for GLP-1 therapy in pill form. Here's what it means for patients and the market.
ReadNews & Blog
EMA/HMA Warn: Surge in Illegal GLP-1 Medicines 2026
The European Medicines Agency (EMA) and national authorities warn of a sharp rise in falsified GLP-1 products - while the UK MHRA tightens safety advice on pancreatitis risks for all GLP-1 receptor agonists.
ReadBPC-157 and GHK-Cu: What the evidence actually shows in 2026
BPC-157 and GHK-Cu are among the most popular peptides, yet their evidence bases could hardly be more different: GHK-Cu has decades of research behind it, while BPC-157 still lacks a single completed randomized human trial.
ReadMelanotan II: Authorities Warn of Severe Risks in 2026
FDA, TGA, and HPRA are warning against Melanotan II: The unapproved tanning peptide can cause melanoma, priapism, and brain swelling - despite an ongoing TikTok trend. An overview of the documented dangers.
ReadLab Tests: 1 in 3 Research Peptides Contaminated
Independent lab tests from 2025/2026 reveal that one in three budget research peptides contains heavy metals, bacterial endotoxins, or the wrong active compound - with purity levels dropping below 80 %.
ReadSafety first
Basics of safe handling.
ReadWelcome to the community
What this is about and why it exists.
Read